top
Search terms
Results 1 - 9 of 9 - ordered by :
Ehjcvp

In this issue of European Heart Journal: Cardiovascular Pharmacology, Johnson et al. report an observational study on the relationship between conventional risk factors and the incidence of AF in ...

European Heart Journal - Cardiovascular Pharmacotherapy, INVITED EDITORIAL, Farhan Shahid, Eduard Shantsila, Gregory Y. H. Lip

Date : 01/04/2016 Item size : 149125 bytes
Ehjcvp

Oral anticoagulation (OAC) is recommended for patients with atrial fibrillation (AF) who are at risk of stroke.1 The CHA2DS2-VASc score, which encompassed a group of common co-morbidities for ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Jo Jo Hai, Hung-Fat Tse

Date : 01/04/2015 Item size : 156814 bytes
Ehjcvp

Abstract Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes, underscoring the importance of choosing anti-diabetic drugs that do not increase ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, R. Kumar, D. M. Kerins, T. Walther

Date : 01/01/2016 Item size : 517106 bytes
Ehjcvp

Introduction The presence of atrial fibrillation (AF) increases the risk of stroke and thrombo-embolism, and given how common AF is, this represents a considerable healthcare and public health ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Gregory Y.H. Lip

Date : 01/04/2015 Item size : 213366 bytes
Ehjcvp

DOACsDirect Oral AnticoagulantsNon-vitamin-K oral anticoagulants NOACs Anticoagulation Coagulation testsIntroduction Unlike vitamin K antagonists (VKAs) such as warfarin that reduce hepatic ...

European Heart Journal - Cardiovascular Pharmacotherapy, Reviews, Tomas Salmonson, Jean-Michel Dogné, Heidi Janssen, Juan Garcia Burgos, Paul Blake

Date : 01/01/2017 Item size : 164607 bytes
Ehjcvp

Effects of reninangiotensinaldosterone system blockade on cardiovascular system The benefits of blocking the RAAS in heart failure (HF) and post-myocardial infarction (MI) were largely proved many ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Gema Ruiz-Hurtado, Luis Miguel Ruilope

Date : 01/04/2015
Ehjcvp

Furthermore, we report advantages and disadvantages of respiratory drugs (β2 agonists, anti-cholinergics, and corticosteroids) administration in COPD patients with CVD. cardiovascular ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Gianluca Campo, Rita Pavasini, Simone Biscaglia, Marco Contoli, Claudio Ceconi

Date : 01/07/2015
Ehjcvp

DOACsDirect Oral AnticoagulantsNon-vitamin-K oral anticoagulants NOACs Anticoagulation Coagulation testsIntroduction Unlike vitamin K antagonists (VKAs) such as warfarin that reduce hepatic ...

European Heart Journal - Cardiovascular Pharmacotherapy, Review, Tomas Salmonson, Jean-Michel Dogné, Heidi Janssen, Juan Garcia Burgos, Paul Blake

Date : 07/12/2016
Ehjcvp

Mean blood glucose changes in the placebo group were 0.6mmol/L (±3.1, P0.0002), 0.2 mmol/L (±2.7, P0.04), and 0.1 mmol/L (±3.0, P0.01) in the moderate, modest, and mild weight loss groups, ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Sadaf Kamil, Nicholas Finer, William Philip T James, Ian D. Caterson, Charlotte Andersson, Christian Torp-Pedersen

Date : 27/09/2016